Functional neuroimaging of sympathetic innervation of the heart

Annals of the New York Academy of Sciences

Volumn 1018, Issue , 2004, Pages 231-243

  Goldstein, David S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Autonomic failure; Dysautonomia; Multiple system atrophy; Norepinephrine; Parkinson disease; Sympathetic

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DOPAMINE DERIVATIVE; FLUORINE 18; LEVODOPA; NORADRENALIN;

AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY SINUS; DEGENERATIVE DISEASE; DEPRESSION; DIABETIC NEUROPATHY; DRUG EFFECT; DYSAUTONOMIA; HEART FAILURE; HEART INNERVATION; HUMAN; MENTAL DISEASE; NEUROCHEMISTRY; NEUROIMAGING; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; PROGNOSIS; SHY DRAGER SYNDROME; SYMPATHETIC INNERVATION; SYSTEMIC DISEASE;

EID: 3242724911     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1296.028     Document Type: Conference Paper

References (115)

1. GOLDSTEIN, D., G. EISENHOFER, D. ROBERTSON, et al. 2002. Dysautonomias: clinical disorders of the autonomic nervous system. Ann. Intern. Med. 137: 753-763.
2. GOLDSTEIN, D.S. 2001. The Autonomic Nervous System in Health and Disease. Marcel Dekker. New York, NY.
3. PACAK, K., M. PALKOVITS, G. YADID, et al. 1998. Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. Am. J. Physiol. 275: R1247-R1255.
4. YOUNG, J.B., R.M. ROSA & L. LANDSBERG. 1984. Dissociation of sympathetic nervous system and adrenal medullary responses. Am. J. Physiol. 247: E35-E40.
5. OLIVER, G. & E.A. SCHAFER. 1895. On the physiological action of extract of the suprarenal capsules. J. Physiol. 17: ix-xiv.
6. ABEL, J.J. & A.C. CRAWFORD. 1897. On the blood-pressure-raising constituent of the suprarenal capsule. Bull. Johns Hopkins Hosp. 8: 151-157.
7. ABEL, J.J. 1902. On a simple method of preparing epinephrin and its compounds. Bull. Johns Hopkins Hosp. 13: 29-36.
8. TAKAMINE, J. 1901. The isolation of the active principle of the suprarenal gland. J. Physiol. 27: 30P-39P.
9. GOLDSTEIN, D.S. & C. TACK. 2000. Non-invasive detection of sympathetic neurocirculatory failure. Clin. Auton. Res. 10: 285-291.
10. BOOTSMA, M., C.A. SWENNE, H.H. VAN BOLHUIS, et al. 1994. Heart rate and heart rate variability as indexes of sympathovagal balance. Am. J. Physiol. 266: H1565-H1571.
11. GRASSI, G. & M. ESLER. 1999. How to assess sympathetic activity in humans. J. Hypertens. 17: 719-734.
12. HAGBARTH, K.E. & D. BURKE. 1977. Microneurography in man. Acta Neurol. (Napoli) 32: 30-34.
13. WALLIN, B.G. & M. ELAM. Microneurography and autonomic dysfunction. In Clinical Autonomic Disorders. P.A. Low, Ed.: 243-252. Little, Brown and Company. Boston, MA.
14. DALE, H.H. 1914. The action of certain esters and ethers of choline, and their relation to muscarine. J. Pharmacol. Exp. Ther. 6: 147-190.
15. LOEWI, O. & E. NAVRATIL. 1926. Uber humorale Ubertragbarkeit der Herzenvenwirkung. X. Mitteilung. Uber das Schicksal des Vagusstoffs. Pflugers Arch. 214: 678-688.
16. AHLQUIST, R.P. 1948. A study of adrenotropic receptors. Am. J. Physiol. 153: 586-600.
17. POLINSKY, R.J., I.J. KOPIN, M.H. EBERT, et al. 1981. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 31: 1-7.
18. BIANCHETTI, M.G., I. MINDER, C. BERETTA-PICCOLI, et al. 1982. Effects of tyramine on blood pressure and plasma catecholamines in normal and hypertensive subjects. Klin. Wochenschr. 60: 465-470.
19. SHANNON, J.R., N.L. FLATTEM, J. JORDAN, et al. 2000. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N. Engl. J. Med. 342: 541-549.
20. JORDAN, J., J.R. SHANNON, B.K. BLACK, et al. 1998. N(N)-nicotinic blockade as an acute human model of autonomic failure. Hypertension 31: 1178-1184.
21. GOLDSTEIN, D.S., E. GROSSMAN, S. LISTWAK, et al. 1991. Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension 18(Suppl. III): III-40-III-48.
22. CHARNEY, D.S., G.R. HENINGER & D.E. REDMOND, JR. 1983. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 33: 19-29.
23. SENARD, J.M., O. RASCOL, G. DURRIEU, et al. 1993. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson disease or multiple system atrophy. Clin. Neuropharmacol. 16: 70-76.
24. BIAGGIONI, I., R.M. ROBERTSON & D. ROBERTSON. 1994. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J. Clin. Pharmacol. 34: 418-423.
25. GOLDSTEIN, D.S. & H.R. KEISER. 1984. Pressor and depressor responses after cholinergic blockade in humans. Am. Heart J. 107: 974-979.
26. BRISTOW, J.D., J. HONOUR, G.W. PICKERING, et al. 1969. Diminished baroreflex sensitivity in high blood pressure. Circulation 39: 48-54.
27. CANNON, W.B. & D. DE LA PAZ. 1911. Emotional stimulation of adrenal gland secretion. Am. J. Physiol. 28: 64-70.
28. CANNON, W.B. 1914. The emergency function of the adrenal medulla in pain and in the major emotions. Am. J. Physiol. 33: 356-372.
29. CANNON, W.B. 1914. The interrelation of emotions as suggested by recent physiological researches. Am. J. Psychol. 25: 256-282.
30. CANNON, W.B. & D. RAPPORT. 1921. Further observations on the denervated heart in relation to adrenal secretion. Am. J. Physiol. 58: 308-337.
31. GOLDSTEIN, D.S., G. FEUERSTEIN, J.L. IZZO, JR., et al. 1981. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci. 28: 467-475.
32. HOLMES, C., G. EISENHOFER & D.S. GOLDSTEIN. 1994. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Biomed. Appl. 653: 131-138.
33. EISENHOFER, G., D.S. GOLDSTEIN, R. STULL, et al. 1986. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin. Chem. 32: 2030-2033.
34. KUWAHARA, T., M. HAMADA & K. HIWADA. 1998. Direct evidence of impaired cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy. J. Nucl. Med. 39: 1486-1491.
35. SAKATA, K., M. SHIROTANI, H. YOSHIDA, et al. 1999. Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. J. Nucl. Med. 40: 6-11.
36. WATANABE, K., M. SEKIYA, T. TSURUOKA, et al. 1999. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J. Hypertens. 17: 1161-1168.
37. OHYA, Y., M. SASAKI, S. FUJISHIMA, et al. 2001. Myocardial imaging with 123I-metaiodobenzylguanidine in essential hypertension and renovascular hypertension. Clin. Exp. Hypertens. 23: 293-304.
38. TAKAHASHI, N., M. NAKAGAWA, T. SAIKAWA, et al. 2001. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J. Am. Coll. Cardiol. 38: 232-237.
39. SIMULA, S., E. VANNINEN, L. VIITANEN, et al. 2002. Cardiac adrenergic innervation is affected in asymptomatic subjects with very early stage of coronary artery disease. J. Nucl. Med. 43: 1-7.
40. AGOSTINI, D., E. LECLUSE, A. BELIN, et al. 1998. Impact of exercise rehabilitation on cardiac neuronal function in heart failure: an iodine-123 metaiodobenzylguanidine scintigraphy study. Eur. J. Nucl. Med. 25: 235-241.
41. KURATA, C., S. SHOUDA, T. MIKAMI, et al. 1998. Metaiodobenzylguanidine and heart rate variability in heart failure. Jpn. Circ. J. 62: 770-772.
42. ATSUMI, H., Y. TAKEISHI, S. FUJIWARA, et al. 1998. Cardiac sympathetic nervous disintegrity is related to exercise intolerance in patients with chronic heart failure. Nucl. Med. Commun. 19: 451-456.
43. MERLET, P., F. POUILLART, J.L. DUBOIS-RANDE, et al. 1999. Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. J. Nucl. Med. 40: 224-231.
44. SAKAMAKI, F., T. SATOH, N. NAGAYA, et al. 2000. Correlation between severity of pulmonary arterial hypertension and 123I-metaiodobenzylguanidine left ventricular imaging. J. Nucl. Med. 41: 1127-1133.
45. DE MILLIANO, P.A., B.L. VAN ECK-SMIT, P.A. VAN ZWIETEN, et al. 2001. Relationship between cardiac metaiodobenzylguanidine uptake and hemodynamic, functional and neurohormonal parameters in patients with heart failure. Eur. J. Heart Fail. 3: 693-697.
46. DE MILLIANO, P.A., J.G. TIJSSEN, B.L. VAN ECK-SMIT, et al. 2002. Cardiac 123 I-MIBG imaging and clinical variables in risk stratification in patients with heart failure treated with beta blockers. Nucl. Med. Commun. 23: 513-519.
47. TAKAHASHI, N., Y. ISHIDA, M. MAENO, et al. 1997. Noninvasive identification of left ventricular involvements in arrhythmogenic right ventricular dysplasia: comparison of 123I-MIBG, 201TlCl, magnetic resonance imaging and ultrafast computed tomography. Ann. Nucl. Med. 11: 233-241.
48. YUKINAKA, M., M. NOMURA, S. ITO, et al. 1998. Mismatch between myocardial accumulation of 123I-MIBG and 99mTc-MIBI and late ventricular potentials in patients after myocardial infarction: association with the development of ventricular arrhythmias. Am. Heart J. 136: 859-867.
49. NOMURA, M., T. NADA, J. ENDO, et al. 1998. Brugada syndrome associated with an autonomic disorder. Heart 80: 194-196.
50. SCHAFERS, M., T. WICHTER, H. LERCH, et al. 1999. Cardiac 123I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation. J. Nucl. Med. 40: 1-5.
51. OKISHIGE, K., T. SASANO, K. YANO, et al. 2001. Serious arrhythmias in patients with apical hypertrophic cardiomyopathy. Intern. Med. 40: 396-402.
52. WICHTER, T., P. MATHEJA, L. ECKARDT, et al. 2002. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 105: 702-706.
53. NAGAOKA, H., T. IIZUKA, S. KUBOTA, et al. 1997. Depressed contractile response to exercise in diabetic patients in the absence of cardiovascular disease: relationship to adrenergic cardiac dysinnervation. Nucl. Med. Commun. 18: 761-770.
54. ZIEGLER, D., F. WEISE, K.J. LANGEN, et al. 1998. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I] metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 41: 443-451.
55. NAGAMACHI, S., S. JINNOUCHI, T. KUROSE, et al. 1998. 123I-MIBG myocardial scintigraphy in diabetic patients: relationship with 201Tl uptake and cardiac autonomic function. Ann. Nucl. Med. 12: 323-331.
56. UEHARA, A., C. KURATA, T. SUGI, et al. 1999. Diabetic cardiac autonomic dysfunction: parasympathetic versus sympathetic. Ann. Nucl. Med. 13: 95-100.
57. GIORDANO, A., M.L. CALCAGNI, A. VERRILLO, et al. 2000. Assessment of sympathetic innervation of the heart in diabetes mellitus using 123I-MIBG. Diabetes Nutr. Metab. 13: 350-355.
58. NAGAMACHI, S., S. JINNOUCHI, T. KUROSE, et al. 2002. Serial change in 123I-MIBG myocardial scintigraphy in non-insulin-dependent diabetes mellitus. Ann. Nucl. Med. 16: 33-38.
59. HATTORI, N., J. RIHL, F.M. BENGEL, et al. 2003. Cardiac autonomic dysinnervation and myocardial blood flow in long-term Type 1 diabetic patients. Diabet. Med. 20: 375-381.
60. AGOSTINI, D., G. BABATASI, A. MANRIQUE, et al. 1998. Impairment of cardiac neuronal function in acute myocarditis: iodine-123-MIBG scintigraphy study. J. Nucl. Med. 39: 1841-1844.
61. KAKUCHI, H., T. SASAKI, Y. ISHIDA, et al. 1999. Clinical usefulness of 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 81: 148-152.
62. TOYAMA, T., Y. AIHARA, T. IWASAKI, et al. 1999. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J. Nucl. Med. 40: 217-223.
63. MOMOSE, M., H. KOBAYASHI, N. IGUCHI, et al. 1999. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl. Med. Commun. 20: 529-535.
64. MERLET, P., C. BENVENUTI, D. MOYSE, et al. 1999. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J. Nucl. Med. 40: 917-923.
65. MAUNOURY, C., D. AGOSTINI, P. ACAR, et al. 2000. Impairment of cardiac neuronal function in childhood dilated cardiomyopathy: an 123I-MIBG scintigraphic study. J. Nucl. Med. 41: 400-404.
66. NARUSE, H., T. ARII, T. KONDO, et al. 2000. Relation between myocardial response to dobutamine stress and sympathetic nerve activation in patients with idiopathic dilated cardiomyopathy: a comparison of 123I-MIBG scintigraphic and echocardiographic data. Ann. Nucl. Med. 14: 427-432.
67. MATSUI, T., T. TSUTAMOTO & M. KINOSHITA. 2001. Relationship between cardiac 123I-metaiodobenzylguanidine imaging and the transcardiac gradient of neurohumoral factors in patients with dilated cardiomyopathy. Jpn. Circ. J. 65: 1041-1046.
68. SHIMIZU, M., H. INO, M. YAMAGUCHI, et al. 2002. Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. J. Nucl. Med. 43: 15-20.
69. MATSUI, T., T. TSUTAMOTO, K. MAEDA, et al. 2002. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments: comparison with neurohumoral factors. Circ. J. 66: 537-543.
70. KASAMA, S., T. TOYAMA, H. HOSHIZAKI, et al. 2002. Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest 122: 542-548.
71. LANZA, G.A. 1999. Abnormal cardiac nerve function in syndrome X. Herz 24: 97-106.
72. LANZA, G.A., A. GIORDANO, C. PRISTIPINO, et al. 2000. Relationship between myocardial 123I-metaiodobenzylguanidine scintigraphic uptake and heart rate variability in patients with syndrome X. Ital. Heart J. 1: 221-225.
73. ABE, Y., T. SUGIURA, K. TAKEHANA, et al. 1999. Clinical significance of denervated but viable myocardium in patients with recanalized acute myocardial infarction. Nucl. Med. Commun. 20: 727-735.
74. BENGEL, F.M., P. BARTHEL, I. MATSUNARI, et al. 1999. Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy. J. Nucl. Med. 40: 904-910.
75. ANDO, M., H. YAMABE, K. SAKURAI, et al. 2002. Relationship between cardiac sympathetic function and baroreceptor sensitivity after acute myocardial infarction. Circ. J. 66: 247-252.
76. SOEKI, T., Y. TAMURA, K. BANDOU, et al. 1998. Long-term effects of the angiotensin-converting enzyme inhibitor enalapril on chronic heart failure: examination by 123I-MIBG imaging. Jpn. Heart J. 39: 743-751.
77. SAKATA, K., M. SHIROTANI, H. YOSHIDA, et al. 1999. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 33: 1447-1452.
78. AGOSTINI, D., A. BELIN, M.H. AMAR, et al. 2000. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J. Nucl. Med. 41: 845-851.
79. LOTZE, U., S. KAEPPLINGER, A. KOBER, et al. 2001. Recovery of the cardiac adrenergic nervous system after long-term beta-blocker therapy in idiopathic dilated cardiomyopathy: assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake. J. Nucl. Med. 42: 49-54.
80. DE MILLIANO, P.A., A.C. DE GROOT, J.G. TIJSSEN, et al. 2002. Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am. Heart J. 144: E3.
81. GOLDSTEIN, D.S., M. KATZPER, O.A. LINARES, et al. 2002. Kinetic model for the fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in the human heart: a novel means to assess cardiac sympathetic neuronal function. Naunyn-Schmiedebergs Arch. Pharmacol. 365: 38-49.
82. SHOUDA, S., C. KURATA, T. MIKAMI, et al. 1999. Effects of extrinsically elevated plasma norepinephrine concentration on myocardial 123I-MIBG kinetics in rats. J. Nucl. Med. 40: 2088-2093.
83. SENARD, J.M., S. RAI, M. LAPEYRE-MESTRE, et al. 1997. Prevalence of orthostatic hypotension in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 63: 584-589.
84. MICIELI, G., E. MARTIGNONI, A. CAVALLINI, et al. 1987. Postprandial and orthostatic hypotension in Parkinson's disease. Neurology 37: 386-393.
85. Cardiovascular disorders in Parkinson disease are underrated. 1999. Fortschr. Neurol. Psychiatr. 67: A8-A9.
86. HILLEN, M.E., M.L. WAGNER & J.I. SAGE. 1996. "Subclinical" orthostatic hypotension is associated with dizziness in elderly patients with Parkinson disease. Arch. Phys. Med. Rehabil. 77: 710-712.
87. GILMAN, S., P. LOW, N. QUINN, et al. 1998. Consensus statement on the diagnosis of multiple system atrophy. Clin. Auton. Res. 8: 359-362.
88. MATHIAS, C.J. 1995. The classification and nomenclature of autonomic disorders: ending chaos, resolving conflict and hopefully achieving clarity. Clin. Auton. Res. 5: 307-310.
89. GOLDSTEIN, D.S., R.J. POLINSKY, M. GARTY, et al. 1989. Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann. Neurol. 26: 558-563.
90. GOLDSTEIN, D.S., C. HOLMES, Y. SHARABI, et al. 2003. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology 60: 1327-1332.
91. POLINSKY, R.J. 1992. Neuropharmacological investigation of autonomic failure. In Autonomic Failure. R. Bannister & C.J. Mathias Eds.: 334-358. Oxford University Press. New York, NY.
92. JORDAN, J., J.R. SHANNON, I. BIAGGIONI, et al. 1998. Contrasting actions of pressor agents in severe autonomic failure. Am. J. Med. 105: 116-124.
93. HAGUE, K., P. LENTO, S. MORGELLO, et al. 1997. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol. (Berl.) 94: 192-196.
94. ORIMO, S., T. OKA, H. MIURA, et al. 2002. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 73: 776-777.
95. BLACK, I.B. & C.K. PETITO. 1976. Catecholamine enzymes in the degenerative neurological disease idiopathic orthostatic hypotension. Science 192: 910-912.
96. SATOH, A., T. SERITA & M. TSUJIHATA. 1997. Total defect of metaiodobenzylguanidine (MIBG) imaging on heart in Parkinson's disease: assessment of cardiac sympathetic denervation. Nippon Rinsho 55: 202-206.
97. SATOH, A., T. SERITA, M. SETO, et al. 1999. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J. Nucl. Med. 40: 371-375.
98. DRUSCHKY, A., M.J. HILZ, G. PLATSCH, et al. 2000. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci. 175: 3-12.
99. BRAUNE, S., M. REINHARDT, R. SCHNITZER, et al. 1999. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53: 1020-1025.
100. YOSHITA, M., M. HAYASHI & S. HIRAI. 1998. Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl. Med. Commun. 19: 137-142.
101. KANZAKI, N., K. SATO & T. HAYABARA. 1997. Improved cardiac iodine-123 metaiodobenzylguanidine accumulation after drug therapy in a patient with Parkinson's disease. Clin. Nucl. Med. 22: 697-699.
102. OHMURA, M. 2000. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J. Nucl. Med. 41: 1594-1595.
103. REINHARDT, M.J., F.D. JUNGLING, T.M. KRAUSE, et al. 2000. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur. J. Nucl. Med. 27: 595-600.
104. BRAUNE, S., M. REINHARDT, J. BATHMANN, et al. 1998. Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol. Scand. 97: 307-314.
105. ORIMO, S., E. OZAWA, T. OKA, et al. 2001. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57: 1140-1141.
106. SENARD, J.M., C. BREFEL-COURBON, O. RASCOL, et al. 2001. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 18: 495-505.
107. TAKATSU, H., H. NISHIDA, H. MATSUO, et al. 2000. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med. 41: 71-77.
108. ORIMO, S., E. OZAWA, S. NAKADE, et al. 1999. (123)I- metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67: 189-194.
109. YOSHITA, M., M. HAYASHI & S. HIRAI. 1997. Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Rinsho Shinkeigaku 37: 476-482.
110. GOLDSTEIN, D.S., C. HOLMES, S.T. LI, et al. 2000. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 133: 338-347.
111. GOLDSTEIN, D.S., C. HOLMES, R. DENDI, et al. 2002. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58: 1247-1255.
112. LI, S.T., R. DENDI, C. HOLMES, et al. 2002. Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann. Neurol. 52: 220-223.
113. GOLDSTEIN, D.S., C. HOLMES, R.O. CANNON, III, et al. 1997. Sympathetic cardioneuropathy in dysautonomias. N. Engl. J. Med. 336: 696-702.
114. AKINCIOGLU, C., M. UNLU & T. TUNC. 2003. Cardiac innervation and clinical correlates in idiopathic Parkinson's disease. Nucl. Med. Commun. 24: 267-271.
115. TAKI, J., K. NAKAJIMA, E.H. HWANG, et al. 2000. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med. 27: 566-573.